Toggle light / dark theme

The United States is considering sampling wastewater taken from international aircraft to track any emerging new Covid-19 variants as infections surge in China, as UK-based health experts estimate about 9,000 people a days are now dying of the disease in China.

The proposed of testing wastewater by the US Centers for Disease Control and Prevention would provide a better solution to tracking the virus and slowing its entry into the US than new travel restrictions announced this week, three infectious disease experts said.

BRUSSELS, Jan 3 (Reuters) — The European Union has offered free COVID-19 vaccines to China, the EU executive said on Tuesday, as infections there surged following Beijing’s relaxation of its “zero-COVID” policies.

China has not responded to the offer yet, a spokesperson for the European Commission told journalists at a regular briefing. He did not specify the amount of vaccines the EU was offering or their manufacturers.

“In view of the COVID situation in China, (Health) Commissioner Stella Kyriakides has reached out to her Chinese counterparts to offer EU solidarity and support,” he said.

Year 2022 😗


Testing multiple treatments for heterogeneous (varying) effectiveness with respect to many underlying risk factors requires many pairwise tests; we would like to instead automatically discover and visualize patient archetypes and predictors of treatment effectiveness using multitask machine learning. In this paper, we present a method to estimate these heterogeneous treatment effects with an interpretable hierarchical framework that uses additive models to visualize expected treatment benefits as a function of patient factors (identifying personalized treatment benefits) and concurrent treatments (identifying combinatorial treatment benefits). This method achieves state-of-the-art predictive power for COVID-19 in-hospital mortality and interpretable identification of heterogeneous treatment benefits. We first validate this method on the large public MIMIC-IV dataset of ICU patients to test recovery of heterogeneous treatment effects. Next we apply this method to a proprietary dataset of over 3,000 patients hospitalized for COVID-19, and find evidence of heterogeneous treatment effectiveness predicted largely by indicators of inflammation and thrombosis risk: patients with few indicators of thrombosis risk benefit most from treatments against inflammation, while patients with few indicators of inflammation risk benefit most from treatments against thrombosis. This approach provides an automated methodology to discover heterogeneous and individualized effectiveness of treatments.

Year 2022 😗


Automation is not just for high-throughput screening anymore. New devices and greater flexibility are transforming what’s possible throughout drug discovery and development. This article was written by Thomas Albanetti, AstraZeneca; Ryan Bernhardt, Biosero; Andrew Smith, AstraZeneca and Kevin Stewart, AstraZeneca for a 28-page DDW eBook, sponsored by Bio-Rad. Download the full eBook here.

A utomation has been a part of the drug discovery industry for decades. The earliest iterations of these systems were used in large pharmaceutical companies for high-throughput screening (HTS) experiments. HTS enabled the testing of libraries of small molecule compounds by a single or a series of multiple experimental conditions to i dentify the potential of those compounds as a treatment for a target disease. HTS has evolved to enable screening libraries of millions of compounds, but the high cost of equipment has largely resulted in automation occurring primarily in large pharmaceutical companies. Today, though, new types of robots paired with sophisticated software tools have helped to democratise access to automation, making it possible for pharma and biotechnology companies of almost any size to deploy these solutions in their labs.

Originally, automated solutions were only implemented for projects that involved a lot of repetitive tasks, which is typical of high-throughput experiments and assays. The equipment used in early automation efforts was expensive, specialised, and physically integrated together, effectively making the equipment unavailable for any non-automated use. Now, both the approaches and equipment are far more adaptive and flexible. The latest automation software is also much simpler to program, making it easier to swap in different instruments and robots as needed. For example, labs can run a particular HTS assay for a few weeks and then quickly pivot to run a new assay. Labs can also create and run bespoke standard operating procedures, assays, and experiments for drug targets they are interested in pursuing.

While “protein” often evokes pictures of chicken breasts, these molecules are more similar to an intricate Lego puzzle. Building a protein starts with a string of amino acids—think a myriad of Christmas lights on a string— which then fold into 3D structures (like rumpling them up for storage).

DeepMind and Baker both made waves when they each developed algorithms to predict the structure of any protein based on their amino acid sequence. It was no simple endeavor; the predictions were mapped at the atomic level.

Designing new proteins raises the complexity to another level. This year Baker’s lab took a stab at it, with one effort using good old screening techniques and another relying on deep learning hallucinations. Both algorithms are extremely powerful for demystifying natural proteins and generating new ones, but they were hard to scale up.

Clustered regularly interspaced short palindromic repeats (CRISPR)-associated Cas9 protein is an effector that plays a major role in a prokaryotic adaptive immune system, by which invading DNA can be targeted and cut for inactivation. The Cas9 endonuclease is directed to target sites by a guide RNA (gRNA) where Cas9 can recognize specific sequences (PAMs) in foreign DNA, which then serve as an anchoring point for cleavage of the adjacent RNA-matching DNA region. Although the CRISPR-Cas9 system has been widely studied and repurposed for diverse applications (notably, genome editing), its origin and evolution remain to be elucidated. Here, we investigate the evolution of Cas9 from resurrected ancient nucleases (anCas) in extinct firmicutes species as old as 2,600 myr to the current day. Surprisingly, we demonstrate that these ancient forms were much more flexible in their PAM and gRNA scaffold requirements compared to modern day Cas9 enzymes. In addition, anCas portrays a gradual paleoenzymatic adaptation from nickase to double-strand break activity, suggesting a mechanism by which ancient CRISPR systems could propagate when harboring Cas enzymes with minimal PAMs. The oldest anCas also exhibit high levels of activity with ssDNA and ssRNA targets, resembling Cas nucleases in related system types. Finally, we illustrate editing activity of the anCas enzymes in human cells. The prediction and characterization of anCas proteins uncovers an unexpected evolutionary trajectory leading to ancient enzymes with extraordinary properties.

R. P-J., B. A-L. are co-inventors on patent application filed by CIC nanoGUNE and licenced to Integra Therapeutics S.L. relating to work in this article. A. S-M. and M.G. are co-founders of Integra Therapeutics S.L. B.P.K is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies. B.P.K. is a consultant for Avectas Inc., EcoR1 capital, and ElevateBio, and is an advisor to Acrigen Biosciences and Life Edit Therapeutics.

When it comes to longevity in the animal kingdom, the Naked mole-rat is often touted as one of the longest living animals known to man, and some say that they functionally do not age, only ever dying of disease or predation. In this article we will investigate these claims, and discover what exactly is so exciting about these aesthetically challenged rodents which has made so many researchers so optimistic about the future of human longevity.

Are Naked Mole-Rats Immortal?

Let’s dispel one of the largest misconceptions about naked mole-rats (Heterocephalus glaber) before we dive into what makes these rodents so interesting. No, naked mole-rats are not immortal in any sense of the word. First documented in 1,842 by German naturalist Eduard Rüppell, we have formally studied this species of rodent for over 180 years, and we have yet to see any immortal naked-mole rats running around, in the wild or otherwise. Neither have we seen a naked mole-rat coming close to the longevity enjoyed by our own species, let alone the longevity enjoyed by other longer lived species such as the giant tortoise. However, it is not the lifespan itself that is so remarkable about the naked mole-rat, but rather its relative longevity compared to other rodents that makes the naked mole-rat so interesting.

For the first time, a new study has identified enlarged perivascular spaces in the brains of migraine sufferers. Results of the study were presented recently at the annual meeting of the Radiological Society of North America (RSNA).

“In people with chronic migraine and episodic migraine without aura, there are significant changes in the perivascular spaces of a brain region called the centrum semiovale,” said study co-author Wilson Xu, an M.D. candidate at Keck School of Medicine of the University of Southern California in Los Angeles. “These changes have never been reported before.”

Migraine is a common, often debilitating condition, involving a severe recurring headache. Migraines may also cause nausea, weakness, and light sensitivity. According to the American Migraine Foundation, over 37 million people in the U.S. are affected by migraine, and up to 148 million people worldwide suffer from chronic migraine.